Mohammed Salhab, MD, is a board certified medical oncologist and hematologist in Golden and Thornton, CO. He treats all cancers in adults, including breast, colorectal, lung, urological, leukemia, lymphoma and multiple myeloma.
Clinical research for lung cancer, small cell and non small cell lung cancer.
Awards & Recognition
2015: Best senior resident
2015: Internal Medicine
2018: Medical Oncology
American Society of Clinical Oncology
American Society of Hematology
Society for Immunotherapy of Cancer
Salhab M, Migdady Y, Donahue M, Xiong Y, Dresser K, Walsh W, Chen BJ, Liebmann J. Immunohistochemical expression and prognostic value of PD-L1 in Extrapulmonary small cell carcinoma: a single institution experience. J Immunother Cancer. 2018 May 29;6(1):42 16. Zhu X,
Salhab M, Donahue M and Walsh W. Pembrolizumab for platinum refractory small cell carcinoma of the prostate, case report. Hematol Med Oncol, 2018
Salhab M, Tomaszewicz K, Meng X, Mathew C et all. Heterogeneous mutational profile and prognosis conferred by TP53 mutations in Appendiceal mucinous neoplasms. Human pathology, 2018
Epperla, N., Maddocks, K. J., Salhab, M., Chavez, J. C., Reddy, N., Karmali, R., Umyarova, E., Bachanova, V., Costa, C., Glenn, M., Calzada, O., Xavier, A. C., Zhou, Z., Hossain, N. M., Hernandez-Ilizaliturri, F. J., Al-Mansour, Z., Barta, S. K., Chhabra, S., Lansigan, F., Mehta, A., Jaglal, M. V., Evans, A., Flowers, C. R., Cohen, J. B., Fenske, T. S., Hamadani, M. and Costa, L. J. (2017), C-MYC-positive relapsed and refractory, diffuse large B-cell lymphoma: Impact of additional “hits”and outcomes with subsequent therapy. Cancer.
Chemaly RF, Vigil KJ, Saad M, Vilar-Compte D, Cornejo-Juarez P, Perez-Jimenez C, Muba-rak S, Salhab M, Jiang Y, Granwehr B, Adachi JA, Raad I. A multicenter study of pandemic influenza A (H1N1) infection in patients with solid tumors in 3 countries. Cancer. 2012 Sep; 118 (18): 4627-4633